Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Weber

Showing results (181-190 of 252) with videos related to

Pageof 26
Sort By:
Journal of Virology|June 16, 2005
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitorsPeter Rusert, Herbert Kuster, Beda Joos, et al.
Pharmacogenetics and Genomics|August 19, 2007
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapyMireia Arnedo, Patrick Taffé, Roland Sahli, et al.
Plos One|November 22, 2011
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionViktor von Wyl, Sara Gianella, Marek Fischer, et al.
Open Forum Infectious Diseases|July 16, 2016
Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort StudyThomas Junier, Margalida Rotger, Emmanuel Biver, et al.
Diabetes Care|February 13, 2008
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyStephane De Wit, Caroline A Sabin, Rainer Weber, et al.
The Journal of Infectious Diseases|April 6, 2005
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disordersPhilip E Tarr, Patrick Taffé, Gabriela Bleiber, et al.
Plos One|October 23, 2010
Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionAdrian Schmid, Sara Gianella, Viktor von Wyl, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2010
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individualsMargalida Rotger, Thomas Gsponer, Raquel Martinez, et al.
European Journal of Preventive Cardiology|April 18, 2015
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) studyNina Friis-Møller, Lene Ryom, Colette Smith, et al.
Pageof 26

Showing results (181-190 of 252) with videos related to

Sort By:
Pageof 26
Journal of Virology|June 16, 2005
Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitorsPeter Rusert, Herbert Kuster, Beda Joos, et al.
Pharmacogenetics and Genomics|August 19, 2007
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapyMireia Arnedo, Patrick Taffé, Roland Sahli, et al.
Plos One|November 22, 2011
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruptionViktor von Wyl, Sara Gianella, Marek Fischer, et al.
Open Forum Infectious Diseases|July 16, 2016
Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort StudyThomas Junier, Margalida Rotger, Emmanuel Biver, et al.
Diabetes Care|February 13, 2008
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyStephane De Wit, Caroline A Sabin, Rainer Weber, et al.
The Journal of Infectious Diseases|April 6, 2005
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disordersPhilip E Tarr, Patrick Taffé, Gabriela Bleiber, et al.
Plos One|October 23, 2010
Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionAdrian Schmid, Sara Gianella, Viktor von Wyl, et al.
Antiviral Therapy|June 3, 2010
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyCatia Marzolini, Luigia Elzi, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2010
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individualsMargalida Rotger, Thomas Gsponer, Raquel Martinez, et al.
European Journal of Preventive Cardiology|April 18, 2015
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) studyNina Friis-Møller, Lene Ryom, Colette Smith, et al.
Pageof 26